Clinical trials: Stable COPD Patients
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01462942
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 197 sites in Austria, Belgium and 20 more
- Volunteers
- 2,443 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Chronic Obstructive Pulmonary Disease
HFNC Effect on BCSS in Patients With COPD
The primary objective of this study is to look for a correlation between the use of high-flow nasal cannula in the outpatient setting in patients with previous chronic obstructive pulmonary disease exacerbation and the change in…
- Trial name
- COPD (NCT02825043)
- Testing
- High-Flow Nasal Cannula
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Oklahoma
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema
- Trial name
- NCT00680056
- Testing
- Formoterol plus Tiotropium
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Federal University of São Paulo
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00358436
- Testing
- Aclidinium bromide
- Where
- 120 sites in United States, Argentina and 5 more
- Volunteers
- 804 people
- Sponsor
- AstraZeneca